Selexipag in the treatment of pulmonary arterial hypertension: Design, development, and therapy

Elizabeth Ashley Hardin, Kelly M. Chin

Research output: Contribution to journalReview article

5 Scopus citations


Pulmonary arterial hypertension is characterized by abnormalities in the small pulmonary arteries including increased vasoconstriction, vascular remodeling, proliferation of smooth muscle cells, and in situ thrombosis. Selexipag, a novel, oral prostacyclin receptor agonist, has been shown to improve hemodynamics in a phase II clinical trial and reduce clinical worsening in a large phase III clinical trial involving patients with pulmonary arterial hypertension. In this paper, we describe the prostacyclin signaling pathway, currently available oral prostanoid medications, and the development and clinical use of selexipag.

Original languageEnglish (US)
Pages (from-to)3747-3754
Number of pages8
JournalDrug Design, Development and Therapy
StatePublished - Nov 15 2016



  • Prostacyclin
  • Pulmonary arterial hypertension
  • Selexipag

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this